Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhonen, T Kuitunen, P Nyandoto & M Kouri

We discuss Pyrhonen's paper as a catalyst for defining systemic therapy approaches in gastric cancer and how the field has evolved in the last two decades in sequential, targeted and more recently immune-directed therapies and how it may develop to transform survival in this cancer of high unmet need.

Automated summary

We discuss how Pyrhonen's paper has become a catalyst for defining systemic therapy approaches in gastric cancer, and the evolution of the field in the last two decades, including sequential, targeted, and more recently immune-directed therapies. We also explore the potential of further development to transform the survival rates in this cancer of high unmet need.